



Every  
moment with  
**VILTEPSO**  
tells a story

 **Viltepso**  
(viltolarsen) injection

Jordan (12 years old),  
a real VILTEPSO patient and  
compensated spokesperson

Getting to know **VILTEPSO**

## **VILTEPSO increases dystrophin, a key protein for supporting muscle health**

- Children taking VILTEPSO showed an average dystrophin level of 5.9% after 20 to 24 weeks of treatment

### **Indication**

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

### **Important Safety Information**

In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.

**Please see Important Safety Information throughout and accompanying Product Information.**

# What is DMD?

Duchenne muscular dystrophy (DMD) is a rare genetic disease that causes a lack of dystrophin, which results in muscles becoming damaged and weaker over time



**DYSTROPHIN:** the protein muscles need to support motor function, which includes daily activities such as walking, running, and climbing



DMD is caused by a **MISSING, OR MUTATED**, part of a gene that prevents the body from making dystrophin



## EARLY DIAGNOSIS IS KEY

to informing management of progressive muscle weakness and decline in function in patients with DMD



Jordan and his father, Jeff.

## Important Safety Information (continued)

Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.

**Please see Important Safety Information throughout and accompanying Product Information.**

 **Viltepso**<sup>®</sup>  
(viltolarsen) injection

# How does VILTEPSO work?

VILTEPSO is an exon 53-skipping therapy that helps the body make its own dystrophin.



## HEALTHY GENE

The DMD gene is made up of exons. These exons work together like building blocks to instruct the body on how to make full-length dystrophin protein.



## DMD GENE MUTATION

A mutation or deletion in the DMD gene may impact the way exons fit together. As you can see, the exons aren't able to connect, resulting in a lack of dystrophin production.



## EXON 53 SKIPPING

VILTEPSO is designed to skip over exon 53. In this case, the orange block is skipped so the green block can fit next to the blue one. In DMD patients amenable to exon 53 skipping, this can result in the production of uninterrupted dystrophin.



## SHORTENED DYSTROPHIN

As the blocks above show, when exon 53 is skipped, shortened dystrophin can be created. **VILTEPSO is proven to help the body make a shortened form of the dystrophin protein.**

## Important Safety Information (continued)

In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.

**Please see Important Safety Information throughout and accompanying Product Information.**

 **Viltepso**<sup>®</sup>  
(viltolarsen) injection




# How does VILTEPSO impact dystrophin production?


## In a clinical trial, VILTEPSO significantly increased dystrophin production

VILTEPSO was studied in 16 ambulatory, or walking, boys aged 4 to younger than 10 years old who were receiving a stable dose of corticosteroids for at least 3 months.

Below, the average dystrophin levels after 20 to 24 weeks of treatment are compared with their average dystrophin levels before treatment.



## 100% of children treated with VILTEPSO in the clinical trial showed an increase in dystrophin levels



VILTEPSO significantly increased dystrophin production at week 25 compared with baseline

## Important Safety Information (continued)

Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.

Please see Important Safety Information throughout and accompanying Product Information.

 **Viltepso**<sup>®</sup>  
(viltolarsen) injection

# VILTEPSO safety overview

**Adverse reactions** reported in  $\geq 10\%$  of DMD patients treated with VILTEPSO 80 mg/kg once weekly

**VILTEPSO  
(80 mg/kg  
once weekly)**

(N=16); n (%)

|                                    |          |
|------------------------------------|----------|
| Upper respiratory tract infection* | 10 (63%) |
| Injection site reaction†           | 4 (25%)  |
| Cough                              | 3 (19%)  |
| Fever                              | 3 (19%)  |
| Bruising                           | 2 (13%)  |
| Muscle and joint pain              | 2 (13%)  |
| Diarrhea                           | 2 (13%)  |
| Vomiting                           | 2 (13%)  |
| Abdominal pain                     | 2 (13%)  |
| Ejection fraction decreased        | 2 (13%)  |
| Hives                              | 2 (13%)  |

\*Upper respiratory tract infection includes the following terms: upper respiratory tract infection, nasopharyngitis, and rhinorrhea.

†Injection site reaction includes the following terms: injection site bruising, injection site erythema, injection site reaction, and injection site swelling.

**Please see Important Safety Information throughout and accompanying Product Information.**



# Taking VILTEPSO

VILTEPSO is a once-weekly intravenous (IV) infusion that can be given by a healthcare professional at your home or at a treatment center. Here are a few other questions you may have:

## Q: What is an infusion?

A: An intravenous infusion goes into the bloodstream through a small needle and tube. It is a FAST way to get medication directly into the body.



## Q: How much medication is in each VILTEPSO dose?

A: Your healthcare provider will calculate the dose based on your child's body weight. 80 MILLIGRAMS of VILTEPSO is given for each kilogram (a kilogram is approximately 2.2 pounds) of your child's weight per week.



## Q: How long is the infusion?

A: The infusion lasts 60 MINUTES. But plan for some extra time before and after treatment in case you have questions for the nurse, or your child needs post-treatment observation.



Jordan's mother, Laura, is a compensated spokesperson.

# How NS Support can help

## Providing personalized access support and customized resources



Our experienced, knowledgeable team at NS Support is dedicated to assisting patients, their caregivers, and healthcare professionals throughout the patient journey to create a smooth path to treatment. We're committed to being here for you every step of the way.



## SUPPORT SERVICES

- Individualized, caring support and resources throughout the patient journey
- Help with understanding insurance coverage for VILTEPSO
- Co-pay Assistance Program—eligible patients may qualify for savings on their deductible, co-pay, and coinsurance for their medication costs for VILTEPSO\*
- Patient Assistance Program—help for uninsured patients in financial need



Eligible patients\* with commercial insurance coverage for treatment are automatically enrolled in the **Co-pay Assistance Program**.

- Savings on their deductible, co-pay, and coinsurance related to their medication costs
- Automatic re-enrollment for the next calendar year

## PATIENT SUPPORT WITH A PERSONAL TOUCH

 **HAVE QUESTIONS? CALL US TODAY**

**833-NSSUPRT (833-677-8778)**

Monday–Friday, 8 AM–8 PM ET

\*Program covers the cost of the medication only and does not cover the costs to administer the infusion. See full Eligibility Requirements & Terms and Conditions on back of brochure.

# Ask your doctor if VILTEPSO can be the next chapter

**VILTEPSO's proven high exon-skipping efficiency means it is effective at producing a vital protein that supports muscle strength**



100% of boys treated with VILTEPSO showed increased dystrophin levels after 20 to 24 weeks of treatment

Sign up for updates at [VILTEPSO.com](https://www.viltepsosupport.com)

## Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

## Important Safety Information

In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.

Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.

For more information about VILTEPSO, see full Prescribing Information. To report SUSPECTED ADVERSE REACTIONS, contact NS Pharma at 1-866-NSPHARM (1-866-677-4276) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](https://www.fda.gov/medwatch).

**Please see Important Safety Information throughout and see accompanying Product Information.**



**NS Pharma**

 **Viltepsos**<sup>®</sup>  
(viltolarsen) injection

© 2022 NS Pharma, Inc. All rights reserved. NS Pharma, the NS Pharma symbol, and Viltepsos are registered trademarks of Nippon Shinyaku Co., Ltd. The NS Support logo is a registered trademark of NS Pharma, Inc. 01/22 US-NS65C-0822